---
document_datetime: 2026-02-19 16:04:42
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/imfinzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: imfinzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.809404
conversion_datetime: 2026-02-21 12:11:37.316073
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Imfinzi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a variation | 12/02/2026                          |                                             | Annex II                         |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000296305                     | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted To extend the due date for the phase III PAES study D9311C00001 (DUO-E) from December 2026 to November 2028 in the RMP and Annex II of the SmPC. In addition, the MAH has taken this opportunity to correct an error identified for the DUO-E study involving a raw data mapping issue that affected the COVID-19 study disruption data and impacts the COVID-19 tables in the CSR. As there is no change in the interpretation or the overall conclusion this has exceptionally been included as part of   |            |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Variation type IA / EMA/VR/0000279103 | A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 13/06/2025 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                       | substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted   |            |             |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| Variation type IB / EMA/VR/0000271882 | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Other changes - Accepted                                             | 05/06/2025 |             |
| PSUR / EMA/PSUR/0000288249            |                                                                                                                                                                                                                                   |            | Maintenance |